1 of 1
Story summary
- China’s fast, cost-effective early clinical trials have made it a global biopharmaceutical powerhouse.
- U.S. lawmakers and FDA officials warned that American pharmaceutical firms increasingly rely on early trials in China.
- They said China’s trial process is opaque and urged keeping medical innovations onshore.
- Foley Hoag partner Xianfeng Morgan Xu said firms may scrutinize China-origin assets more closely amid Washington rhetoric.